HB8573, the “Safeguarding The Overall Protection of Minors Act” or “STOP Act,” would prohibit gender transition procedures on minors and create federal enforcement mechanisms to deter and penalize such care. The bill defines “gender transition procedure” broadly to include puberty blockers, cross-sex hormones, and a wide range of surgical and cosmetic procedures, while carving out exceptions for certain intersex/disorders of sex development care, treatment of complications from prior procedures, precocious puberty, emergency treatment for serious physical conditions, and male circumcision.
The bill would make it unlawful for any person to knowingly perform, attempt to perform, conspire to perform, or aid or abet a gender transition procedure on a minor when the conduct involves interstate commerce, federal jurisdiction, or related communications or payments. It authorizes the Secretary of Health and Human Services to impose civil monetary penalties of at least $100,000 per violation, allows the Department of Justice to collect those penalties, and creates a private right of action for the minor’s parent, guardian, or caretaker to seek compensatory, emotional-distress, and punitive damages. It also establishes a federal “Victims of Gender Transition Procedures Compensation Fund” and a grant program to support “detransition” services, including medical reversal care, mental health services, and education/employment assistance.
The bill would significantly affect federal health policy and civil liability rules by creating new statutory prohibitions, enforcement authority, and funding streams tied to gender-affirming care for minors. It would also reach health care professionals, employers, and other persons involved in providing or facilitating such procedures, while expressly stating that minors themselves would not be liable. In addition, the bill would restrict grant eligibility for entities that perform or support gender transition procedures or most abortions, and it would impose long limitations periods for civil suits related to alleged violations.
Because no committee transcripts or votes are provided, the available context shows only that the bill was introduced and referred to the House Committees on Energy and Commerce and the Judiciary. The bill’s text suggests a strongly oppositional posture toward gender-affirming treatment for minors and a supportive posture toward detransition services, but there is no recorded floor or committee sentiment in the materials provided. Based on the bill’s structure and language, it is likely to be viewed as highly controversial, especially among medical providers, LGBTQ advocates, and civil liberties groups, while supporters would likely frame it as a child-protection measure.
The main points of contention are the breadth of the definition of prohibited procedures, the federal intrusion into medical decision-making, and the bill’s civil-penalty and private-litigation scheme. Critics would likely object to the inclusion of puberty blockers and hormone therapy, the use of terms such as “mutilation,” and the retroactive exposure of providers to liability; supporters would likely emphasize the age-based prohibition, the exceptions for emergencies and intersex conditions, and the bill’s stated purpose of protecting minors and supporting detransition.
The bill would add a new federal prohibition on gender transition procedures for minors and create HHS civil-penalty authority, DOJ collection authority, and a private right of action for affected families. It would also establish a federal compensation fund and a grant program for detransition-related services, while affecting the conduct and liability exposure of health care professionals, employers, and entities that provide or refer for such care. The measure would not amend a specific existing statute in the text provided, but it would create new federal standards that could preempt or conflict with state medical practice rules and existing standards of care in jurisdictions that allow gender-affirming treatment for minors.
No votes or committee discussion are provided, so there is no recorded legislative sentiment in the supplied materials. The bill’s introduction and referral indicate it is still in the early committee stage. Based on the text alone, the bill appears to be strongly supported by sponsors who favor restricting gender transition care for minors and strongly opposed by groups that support access to gender-affirming medical treatment.
The most notable contention is over whether the bill protects minors or unlawfully restricts medically appropriate care. Opponents are likely to focus on the broad definition of prohibited procedures, the inclusion of puberty blockers and hormone therapy, the retroactive liability provisions, and the bill’s characterization of gender transition care; supporters are likely to emphasize the age cutoff, the civil-penalty framework, and the exceptions for intersex conditions, emergencies, and precocious puberty. The grant restrictions tied to abortion and the bill’s federal enforcement structure are also likely to draw criticism from reproductive-rights and medical-privacy advocates.